A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator ' s Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell Interventions: Biological: Liso-cel; Drug: Idelalisib; Drug: Rituximab; Drug: Bendamustine; Drug: Fludarabine; Drug: Cyclophosphamide Sponsors: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Celgene Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials